智通财经APP获悉,默沙东(MRK.US)预计将在今年年底前推出其畅销癌症治疗药物Keytruda的一种更易于管理的版本,从而加快该公司保护其畅销药物免受定价压力的努力。
公司首席执行官罗布•戴维斯(Rob Davis)周一在旧金山举行的摩根大通医疗保健会议上表示,最新版本的Keytruda最终可能会占据原来版本30%至40%的市场份额。Keytruda每年带来近300亿美元的收入,预计将于2028年失去专利保护,预计将在本十年末之前接受医疗保险谈判。
这种新型药物可以通过皮下注射(通过针头在皮肤下注射)而不是静脉输液,可将给药时间从半小时缩短到大约三分钟。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.